Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.92 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.92 |
| ▸ | ADH1B | P00325 | 3/20 | 0.50 |
| ▸ | ADH1C | P00326 | 3/20 | 0.50 |
| ▸ | ADH1A | P07327 | 3/20 | 0.50 |
| ▸ | ADH4 | P08319 | 1/20 | 0.50 |
| ▸ | ADH7 | P40394 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5909148 | 1.00 | ALDH1A1 (0.92) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| SCHEMBL1679056 | 1.00 | ALDH1A1 (0.92) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| SCHEMBL1679059 | 1.00 | ALDH1A1 (0.92) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| Hydrochloric Acid SCHEMBL3247210 | 0.96 | ALDH1A1 (0.86) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| SCHEMBL24839013 | 0.96 | ALDH1A1 (1.00) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| SCHEMBL24771540 | 0.96 | ALDH1A1 (1.00) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| SCHEMBL18657086 | 0.96 | ALDH1A1 (1.00) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| SCHEMBL24771539 | 0.96 | ALDH1A1 (1.00) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| SCHEMBL20733078 | 0.96 | ALDH1A1 (1.00) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| SCHEMBL21375316 | 0.96 | ALDH1A1 (1.00) | ALDH1A1HSD17B10ADH1BADH1CADH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4565588-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | Suzhou Keen Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| WO-2023241620-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2023-12-21 | — | — | WO | disclosed |
| CN-116334018-A | Heat-resistant reductive amination enzyme and preparation method and application thereof | 上海交通大学 | 2023-06-27 | — | — | CN | disclosed |
| CN-116334153-A | Reductive amination enzyme and preparation method and application thereof | 上海交通大学 | 2023-06-27 | — | — | CN | disclosed |
| US-20230146483-A1 | 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER | NXERA PHARMA UK LIMITED (GB) | 2023-05-11 | — | — | US | disclosed |
| US-20230033021-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN INTEGRIN INHIBITOR | GLAS USA LLC | 2023-02-02 | — | — | US | disclosed |
| EP-4122441-A1 | CROSSLINKED HYALURONIC ACID-COLLAGEN GELS FOR IMPROVING TISSUE GRAFT VIABILITY AND SOFT TISSUE AUGMENTATION | ALLERGAN, INC. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-9845314-B2 | Pyrazolyl-substituted heteroaryls and their use as medicaments | BOEHRNGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-12-19 | — | — | US | disclosed |
| US-20170073333-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-16 | — | — | US | disclosed |
| EP-0670838-A1 | SUBSTITUTED-PHENYL(N,N'-CYCLOALKYL/ALKYL CARBOXAMIDE)-1H/3H-IMIDAZO 4,5-b]PYRIDINE COMPOUNDS AS PAF ANTAGONISTS | G.D. SEARLE & CO. (US) | 1995-09-13 | — | — | EP | disclosed |
| US-5359073-A | Substituted-phenyl (N,N'-cycloalkyl/alkyl carboxamide)-1H/3H-imidazo[4,5-b]pyridine compounds as PAF antagonists | G. D. SEARLE & CO. (US) | 1994-10-25 | — | — | US | disclosed |
| WO-1994017063-A1 | N,N'-CYCLOALKYL/ALKYL CARBOXAMIDE 4H-IMIDAZO[4,5-b]PYRIDINE COMPOUNDS AS PAF ANTAGONISTS | G.D. SEARLE & CO. (US) | 1994-08-04 | — | — | WO | disclosed |
| WO-1994012500-A1 | SUBSTITUTED-PHENYL(N,N'-CYCLOALKYL/ALKYL CARBOXAMIDE)-1H/3H-IMIDAZO[4,5-b]PYRIDINE COMPOUNDS AS PAF ANTAGONISTS | G.D. SEARLE & CO. (US) | 1994-06-09 | — | — | WO | disclosed |
| US-5262426-A | Treatment of cardiovascular disorders, antiinflammatory agents | G. D. SEARLE & CO. (US) | 1993-11-16 | — | — | US | disclosed |
| US-5204353-A | 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith | CIBA-GEIGY CORPORATION (US) | 1993-04-20 | — | — | US | disclosed |
| EP-0288431-B1 | 3H-1,2,3-triazolo[4,5-d]pyrimidines | CIBA-GEIGY AG (CH) | 1992-08-19 | — | — | EP | disclosed |
| US-5110818-A | Antiepileptic agents | CIBA-GEIGY CORPORATION (US) | 1992-05-05 | — | — | US | disclosed |
| EP-0363320-A2 | Substituted 9H purine | CIBA-GEIGY AG (CH) | 1990-04-11 | — | — | EP | disclosed |
| EP-0288431-A1 | 3H-1,2,3-triazolo[4,5-d]pyrimidines | CIBA-GEIGY AG (CH) | 1988-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146483-A1 | 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER | ADORA2A, ADORA1, ADORA3 | ALDH1A1 111/4885HSD17B10 2963/4885ADH1B 488/4885 |
| US-20230033021-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN INTEGRIN INHIBITOR | ITGAL, ITGB2, ITGB1 | ALDH1A1 2098/4885HSD17B10 3129/4885ADH1B 2701/4885 |
| US-20170073333-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | HRH4, HRH2, HRH3 | ALDH1A1 1117/4885HSD17B10 1648/4885ADH1B 1103/4885 |
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | ALDH1A1 256/4885HSD17B10 1120/4885ADH1B 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.